Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, sucroferric oxyhydroxide (Velphoro®) cannot be endorsed for use within NHS Wales for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis. |
||
|
||
Medicine details |
||
| Medicine name | sucroferric oxyhydroxide (Velphoro®) | |
| Formulation | 500 mg chewable tablet | |
| Reference number | 4775 | |
| Indication | Control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis |
|
| Company | Vifor Fresenius Medical Care Renal Pharma UK Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/05/2021 | |